EUVIMEDEUVIMED entdecken
Crossref

Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer

Siyeon Park, Seongyeol Park, Tae Min Kim, Soyeon Kim, Jaemoon Koh, Joonoh Lim, Kijong Yi, Boram Yi, Young Seok Ju, Miso Kim, Bhumsuk Keam, Jung Sun Kim und 4 weitere

European Journal of Cancer · 2024-09 · 208 · 114206

DOI: 10.1016/j.ejca.2024.114206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Siyeon Park und 15 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University Cancer Research Institute, Seoul, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, ErbB Receptors, Exons. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmErbB ReceptorsExonsLung NeoplasmsTyrosine Kinase InhibitorsHumansCell Line, TumorMutagenesis, InsertionalMutation

Stichwörter der Autor:innen

AmivantamabEGFR exon 20 insertionsMobocertinibNSCLCResistance

Substanzen

EGFR protein, humanErbB ReceptorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Seoul National University Cancer Research Institute, Seoul, South Korea.
  • Inocras Inc., San Diego, CA, USA; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
  • Seoul National University Cancer Research Institute, Seoul, South Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: gabriel9@snu.ac.kr.
  • Seoul National University Cancer Research Institute, Seoul, South Korea; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, South Korea.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
  • Inocras Inc., San Diego, CA, USA.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Park, S., Park, S., Kim, T. M., Kim, S., Koh, J., Lim, J., Yi, K., Yi, B., Ju, Y. S., Kim, M., Keam, B., Kim, J. S., Jeon, Y. K., Kim, D. W., Kim, Y. T., & Heo, D. S. (2024). Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer. European Journal of Cancer, 208, 114206. https://doi.org/10.1016/j.ejca.2024.114206

Vancouver

Park S, Park S, Kim TM, Kim S, Koh J, Lim J, et al. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer. European Journal of Cancer. 2024;208:114206. doi:10.1016/j.ejca.2024.114206

BibTeX
@article{Park2024,
  author = {Park, Siyeon and Park, Seongyeol and Kim, Tae Min and Kim, Soyeon and Koh, Jaemoon and Lim, Joonoh and Yi, Kijong and Yi, Boram and Ju, Young Seok and Kim, Miso and Keam, Bhumsuk and Kim, Jung Sun and Jeon, Yoon Kyung and Kim, Dong-Wan and Kim, Young Tae and Heo, Dae Seog},
  title = {Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {208},
  pages = {114206},
  doi = {10.1016/j.ejca.2024.114206}
}
Kostenlos starten →